This post uses hypothetical scenarios for illustrative purposes only. It does not describe any actual client, transaction, or representation, and is not legal advice.
Imagine a Florida founder in the middle of an exit conversation, running the standard three options. Sell to a strategic and lose the culture. Sell to private equity and roll twenty percent into a sponsor’s second bite. Or sell to an employee stock ownership plan and keep the business independent while getting liquidity. Somewhere in the third conversation, an advisor says the words “1042 rollover” and “tax-free exit,” and the founder’s attention locks on.
Here is the part that gets skipped in that pitch, and it matters more in Florida than almost anywhere else: § 1042 is a deferral, not an exclusion, and the value of a deferral depends heavily on which taxes you were going to pay. A Florida seller has a shorter list than most.
The Section 1042 election has four requirements and one uncomfortable condition
Internal Revenue Code § 1042 lets a selling shareholder defer capital gain on a sale of employer securities to an ESOP, provided several conditions are met.
First, the company must be a C corporation at the time of the sale. Second, the seller must have held the stock for at least three years and must not have received it through a qualified plan or a compensatory option exercise. Third, the ESOP must own at least thirty percent of the company’s stock immediately after the transaction. Fourth, the seller must reinvest the proceeds in qualified replacement property within a fifteen-month window that opens three months before the sale and closes twelve months after it.
Qualified replacement property is narrower than founders expect. It means securities — stock, bonds, debentures — issued by a domestic operating corporation that does not derive more than twenty-five percent of its gross receipts from passive investment income and is not part of the issuer’s controlled group. It excludes mutual funds. It excludes exchange-traded funds. It excludes REITs, municipal bonds, and government securities. A founder who wanted to sell the company and put the proceeds into an index fund cannot make the election and do that. The workaround the market uses — long-dated floating rate notes issued by large domestic corporates, margined to generate diversified investment capacity — works, but it is a structured product with its own costs, counterparty considerations, and complexity, and it locks the position for as long as the deferral is meant to last.
The uncomfortable condition is the C corporation requirement. Most closely held Florida operating companies of the size that fit an ESOP are S corporations. To make the § 1042 election, the company converts to C status before the transaction. The statute itself imposes no minimum holding period for C status, so the conversion can be immediate. What it costs is the thing that makes ESOPs interesting in the first place.
The S corporation ESOP is the structure the deferral makes you give up
An ESOP is a tax-exempt trust. When an ESOP owns stock in an S corporation, the ESOP’s share of the corporation’s income flows through to a tax-exempt shareholder and is not subject to federal income tax. In a one hundred percent S corporation ESOP, the operating company effectively pays no federal income tax at all. That is not a deferral. That is a permanent structural change in the company’s after-tax cash flow, and it is the single largest reason ESOPs can outbid strategic buyers on a debt-financed basis — the company services the acquisition note with pre-tax dollars.
So the founder faces a real trade. Convert to C, take the § 1042 deferral on the founder’s own gain, and hand the company back a corporate-level federal tax bill going forward. Or stay S, forgo the deferral, pay the capital gains tax at closing, and leave the company operating federal-income-tax-free.
That trade is priced differently depending on where the seller lives, and this is the Florida point.
What the deferral is worth is a different number in Florida
A § 1042 election defers federal capital gains tax and, in most states, state capital gains tax as well, because most states conform. For a seller in a high-rate state, the combined deferral can approach a third of the gain, and the case for converting to C and making the election is strong on the seller’s side of the ledger alone.
Florida has no personal income tax. A Florida-resident founder selling stock has no state capital gains tax to defer. The § 1042 election therefore buys deferral of the federal rate and the net investment income tax, and nothing else. The state-level increment that makes the election compelling elsewhere simply is not in the calculation.
That does not make the election worthless — deferral of a federal capital gains liability is real money, and where the seller holds the qualified replacement property until death, the basis adjustment at death can convert the deferral into permanent forgiveness for the heirs. That outcome is the strongest version of the § 1042 case, and it is an estate plan as much as a deal structure. But the founder who intends to spend the proceeds, diversify freely, or fund another venture in three years is trading a permanent corporate-level tax benefit for a deferral they will unwind anyway.
The same logic that makes founders think carefully before establishing Florida domicile ahead of a sale cuts the other direction here: once you are already in a no-income-tax state, the marginal value of every state-tax-driven planning technique drops. It is worth running the two scenarios with actual numbers — the company’s projected taxable income under C status against the seller’s deferral benefit — before anyone converts anything.
Adequate consideration is the fiduciary risk, and the rules are still unwritten
The other half of ESOP diligence has nothing to do with tax. ERISA prohibits a plan from acquiring employer securities for more than “adequate consideration,” and the trustee that overpays — even in good faith, even on an appraisal — is exposed to a prohibited transaction claim from the Department of Labor. Two decades of DOL enforcement have been built on that theory, and the resulting settlements have shaped how transactions are structured, valued, and papered.
What has not happened is a rule. EBSA first proposed adequate consideration regulations in 1988 and never finalized them. SECURE 2.0 § 346 directed the Secretary of Labor to issue formal guidance on acceptable standards and procedures for establishing good faith fair market value of shares acquired by an ESOP. Draft proposed regulations were released in January 2025 and withdrawn days later under the incoming administration’s regulatory freeze, before publication in the Federal Register. As of mid-2026, the Department’s regulatory agenda targets a replacement proposal in November 2026, following pre-rule stakeholder outreach. Agenda dates are aspirational, the content of any replacement proposal may differ substantially, and the companion prohibited transaction class exemption remains unresolved.
The practical consequence for a founder selling in the meantime is that the standard is still defined by litigation and settlement practice rather than by regulation. That argues for an independent trustee retained early and genuinely independent, a valuation firm the trustee selects rather than the seller, a documented negotiation record showing the trustee pushed on price and terms, and a fairness opinion that addresses the financing terms and not only the equity value. It also argues against seller financing on terms the trustee did not meaningfully negotiate, since seller notes with warrants have been a recurring feature of the enforcement cases.
The 2028 change, and why it does not rescue the S corporation seller
SECURE 2.0 § 114 extends § 1042 deferral to sales of S corporation stock to an ESOP, effective for sales made after December 31, 2027. Founders sometimes hear that and conclude the C-versus-S trade is about to disappear.
It is not. The S corporation version of the election is capped at ten percent of the amount realized. On a ten million dollar sale, that is a deferral opportunity on one million dollars, not on ten. Every other § 1042 requirement — the thirty percent post-transaction ESOP ownership, the three-year holding period, the fifteen-month qualified replacement property window, the narrow definition of qualified replacement property — continues to apply to that ten percent slice.
For a founder timing an exit around it, the honest read is that § 114 is a modest sweetener for sellers who were going to stay S anyway, not a reason to defer a 2026 transaction into 2028.
Where this sits against the other exits
An ESOP is not a better deal than a strategic sale in every case, and the comparison is rarely apples to apples. An ESOP pays fair market value as determined by an independent appraisal, which does not include the control premium or the synergy value a strategic buyer might pay. It is generally financed with a combination of third-party senior debt and a seller note, which means the founder carries paper and credit risk that a cash strategic sale would not create. What it buys is continuity, a workforce that participates in the equity, and — in the S corporation structure — a company that keeps considerably more of what it earns.
For founders comparing outcomes across structures, it is worth running the ESOP against the same models used for a § 338(h)(10) election and against the § 1202 qualified small business stock analysis, since a founder holding QSBS-eligible C corporation stock may already have a federal exclusion that makes a § 1042 deferral redundant. Those two provisions are not additive, and running them in the same model is the fastest way to see which one is actually doing the work.
If you are a Florida founder evaluating an ESOP against a strategic or sponsor sale and working through the § 1042 and S-corporation trade-offs, feel free to reach out to our firm manager, Magda, at Magda@montague.law, or fill out our contact form. Mention you read this post.
